Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease

Systemic Treatment and Drug Resistance

At a Glance

Aspergillus niger lung infections generally need prolonged systemic antifungal treatment. The choice of drug depends on whether infection is chronic or invasive, susceptibility testing, and tolerance, while blood levels, liver or kidney tests, and interactions help keep treatment safe.

When Aspergillus niger causes an infection in the lungs, treatment usually requires a long-term commitment to powerful medications known as systemic antifungals [1]. Unlike ear infections that use drops, lung infections require medications that travel through your entire system, either as pills or through an IV [1][2].

Standard Treatment Options

The first line of defense for lung infections caused by Aspergillus is a class of drugs called azoles [3].

  • For Chronic Infection (CPA): Itraconazole or voriconazole are common oral options, but posaconazole and other approaches may be considered. These are often given for at least six months, adjusted to response [1][4].
  • For Invasive Infection (IPA): Because these infections move quickly, doctors often start with voriconazole or isavuconazole [5][2]. Treatment usually lasts at least six to twelve weeks, adjusted to response and immune recovery.
  • Alternative Options: If the fungus is resistant to azoles or if you cannot take them, doctors may use liposomal amphotericin B (given by IV) as an alternative in selected cases. Echinocandins such as micafungin are not routine monotherapy for primary IPA and are generally reserved for selected combination or salvage situations under specialist care [1][5].

The Role of Susceptibility Testing

Antifungal susceptibility testing is particularly important with treatment failure, prior azole exposure, suspected resistance, or an invasive isolate when the result will change therapy [6][7]. This is a lab test where scientists try to kill your specific strain of fungus with different drugs to see which ones work best.

This is especially critical for A. niger and its relatives because their resistance can be unpredictable:

  • Variable Resistance: Some strains of A. niger and its “cryptic” relative A. tubingensis have shown variable in-vitro findings of reduced sensitivity to common azoles like itraconazole and voriconazole [8][9].
  • Species Differences: A. tubingensis is often more resistant to medications than “true” A. niger [9][10].
  • Evolving Science: Because the genetic reasons for this resistance are not as well-understood in A. niger as they are in other species, doctors cannot simply look at the DNA; they must perform a physical “growth test” (phenotypic testing) to be sure the drug will work [10][9].

Monitoring Your Treatment

Because treatment for chronic lung infections is often prolonged, your doctor will monitor you closely for safety and effectiveness [1][4].

Therapeutic Drug Monitoring (TDM)

For drugs like voriconazole and itraconazole, “one size does not fit all.” Your body may process these drugs faster or slower than someone else’s [11].

  • Blood Tests: You will have regular blood draws to check the “trough level” (the lowest level of the drug in your system before your next dose) [11][12].
  • The Target Range: Targets vary by guideline, assay, indication, toxicity risk, and local practice, and patients should not adjust doses themselves [11].

Safety and Side Effects

Long-term azole therapy requires regular check-ups to monitor for:

  • Liver Health: These drugs can stress the liver, so you will have regular liver function tests (blood work) to check for hepatotoxicity [13][14]. Seek prompt medical contact for jaundice, dark urine, or severe rash.
  • Drug Interactions: Azoles interact with many other common medications, including some blood thinners, statins, and anti-rejection drugs [15][16]. Always tell your doctor about every medication and supplement you take.
  • Specific Side Effects:
    • Voriconazole can cause vision changes, skin rashes, and extreme sensitivity to sunlight [16][17]. It carries a long-term photosensitivity-related skin cancer risk, and severe or persistent visual/neuropsychiatric effects.
    • Itraconazole can sometimes cause fluid retention and carries a risk of associated heart failure [14][18].
    • Nerve Issues: Long-term use of these drugs can occasionally cause numbness or tingling in the hands and feet (peripheral neuropathy) [16].
    • Amphotericin B: requires renal and electrolyte monitoring.
Medication Common Use Key Monitoring Notable Side Effects
Itraconazole Chronic (CPA) Blood levels (TDM), Liver tests Stomach upset, fluid retention, heart failure risk [14]
Voriconazole Invasive (IPA) / CPA Blood levels (TDM), Liver tests Vision shifts, sun sensitivity, skin cancer risk [16]
Isavuconazole Invasive (IPA) Liver tests Generally better tolerated [16]
Amphotericin B Severe / Resistant Kidney function, Electrolytes Kidney stress, fever/chills (IV) [1]

Common questions in this guide

What medicines are used to treat an Aspergillus niger lung infection?
Lung infections usually require systemic antifungal medicine that reaches the whole body, rather than ear drops. Chronic pulmonary infection is commonly treated with itraconazole or voriconazole for at least six months, while invasive pulmonary infection often starts with voriconazole or isavuconazole and lasts six to 12 weeks or longer. The treating clinician adjusts the plan based on response, immune recovery, and safety.
What does antifungal susceptibility testing show for A. niger?
A laboratory exposes the patient’s fungal isolate to different antifungal medicines to see which drugs inhibit its growth. This test is especially useful if treatment is not working, there has been prior azole use, resistance is suspected, or the result could change therapy. It can be important because A. niger and the related A. tubingensis can have variable azole sensitivity.
Why do I need a voriconazole or itraconazole blood-level test?
These tests measure the drug level in your blood, often at the lowest point just before the next dose. People process these medicines at different speeds, so the result helps the clinician assess whether exposure may be too low or too high and whether a dose change is needed. Do not change the dose yourself.
How is my health monitored during long-term Aspergillus treatment?
Long-term azole treatment commonly includes liver function blood tests, medication reviews, and, for voriconazole or itraconazole, therapeutic drug monitoring. Tell the care team about every prescription, over-the-counter medicine, and supplement because azoles can interact with blood thinners, statins, and anti-rejection medicines. Amphotericin B requires kidney and electrolyte monitoring.
What side effects should I report while taking antifungals for Aspergillus?
Seek prompt medical contact for jaundice, dark urine, or a severe rash. Also report vision changes, marked sun sensitivity, persistent changes in vision, mood, or thinking, swelling or fluid retention, numbness or tingling, or fever and chills during intravenous amphotericin B. Your clinician can determine whether symptoms are a side effect and whether treatment needs to change.
What are the options if Aspergillus niger does not respond to an azole?
Doctors may use liposomal amphotericin B through an IV in selected cases when azoles cannot be used or the fungus is resistant. Echinocandins such as micafungin are generally not used alone as the routine initial treatment for invasive pulmonary aspergillosis, but may be considered in selected combination or salvage situations under specialist care.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Aspergillus niger infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my 'voriconazole trough level' and does my current dose need to be adjusted to stay in the target range?
  2. 2.Has the lab performed antifungal susceptibility testing to see if the A. niger is sensitive to the medication I am taking?
  3. 3.What are the results of my baseline liver function tests and how often will you monitor them during this treatment?
  4. 4.Are any of my current medications, such as blood thinners or statins, going to interact with my antifungal treatment?
  5. 5.Since this treatment may last 6 to 12 months, what signs of long-term side effects, like nerve pain or sun sensitivity, should I look for?
  6. 6.If this treatment fails or I can't tolerate it, is liposomal amphotericin B or an echinocandin a viable alternative for me?

References

References (18)
  1. 1

    Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist.

    Bongomin F, Asio LG, Baluku JB, et al.

    Journal of fungi (Basel, Switzerland) 2020; (6(2)) doi:10.3390/jof6020075.

    PMID: 32498415
  2. 2

    Treatment of Aspergillosis.

    Jenks JD, Hoenigl M

    Journal of fungi (Basel, Switzerland) 2018; (4(3)) doi:10.3390/jof4030098.

    PMID: 30126229
  3. 3

    Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

    Denning DW, Cadranel J, Beigelman-Aubry C, et al.

    The European respiratory journal 2016; (47(1)):45-68 doi:10.1183/13993003.00583-2015.

    PMID: 26699723
  4. 4

    An overview of the available treatments for chronic cavitary pulmonary aspergillosis.

    Sehgal IS, Dhooria S, Muthu V, et al.

    Expert review of respiratory medicine 2020; (14(7)):715-727 doi:10.1080/17476348.2020.1750956.

    PMID: 32249630
  5. 5

    Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005).

    Wichmann D, Hoenigl M, Koehler P, et al.

    Infection 2025; (53(4)):1299-1310 doi:10.1007/s15010-025-02572-2.

    PMID: 40465080
  6. 6

    Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section Nigri isolates from the lower respiratory tract.

    Takeda K, Suzuki J, Watanabe A, et al.

    Medical mycology 2020; (58(3)):310-314 doi:10.1093/mmy/myz072.

    PMID: 31240316
  7. 7

    The clinical significance of Aspergillus-positive respiratory samples.

    Katriina P, Veli-Jukka A, Ulla H

    Mycoses 2023; (66(5)):387-395 doi:10.1111/myc.13566.

    PMID: 36654511
  8. 8

    Drug Sensitivity and Resistance Mechanism in Aspergillus Section Nigri Strains from Japan.

    Hashimoto A, Hagiwara D, Watanabe A, et al.

    Antimicrobial agents and chemotherapy 2017; (61(8)) doi:10.1128/AAC.02583-16.

    PMID: 28607016
  9. 9

    Reduced Activity of Triazole Antifungal Agents Against Aspergillus tubingensis From a Global Collection of Genomically-Characterized Aspergillus Section Nigri Clinical Isolates (2020-2023).

    Kimbrough JH, Winkler ML, Karr MH, et al.

    Mycoses 2026; (69(7)):e70197 doi:10.1111/myc.70197.

    PMID: 42415524
  10. 10

    New Insights into the Cyp51 Contribution to Azole Resistance in Aspergillus Section Nigri.

    Pérez-Cantero A, López-Fernández L, Guarro J, Capilla J

    Antimicrobial agents and chemotherapy 2019; (63(7)) doi:10.1128/AAC.00543-19.

    PMID: 31061160
  11. 11

    Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.

    Stott KE, Hope WW

    The Journal of antimicrobial chemotherapy 2017; (72(suppl_1)):i12-i18 doi:10.1093/jac/dkx029.

    PMID: 28355463
  12. 12

    Approaches for posaconazole therapeutic drug monitoring and their clinical benefits.

    Wang S, Li C, Dong Y, Dong W

    European journal of clinical pharmacology 2024; (80(12)):1845-1855 doi:10.1007/s00228-024-03756-9.

    PMID: 39249114
  13. 13

    Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient.

    Bühler T, Medinger M, Bouitbir J, et al.

    Frontiers in pharmacology 2019; (10()):645 doi:10.3389/fphar.2019.00645.

    PMID: 31244659
  14. 14

    Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

    Jović Z, Janković SM, Ružić Zečević D, et al.

    European journal of drug metabolism and pharmacokinetics 2019; (44(2)):139-157 doi:10.1007/s13318-018-0513-7.

    PMID: 30284178
  15. 15

    Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

    Groll AH, Townsend R, Desai A, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2017; (19(5)) doi:10.1111/tid.12751.

    PMID: 28722255
  16. 16

    Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives.

    Alastruey-Izquierdo A, Cadranel J, Flick H, et al.

    Respiration; international review of thoracic diseases 2018; (96(2)):159-170 doi:10.1159/000489474.

    PMID: 29982245
  17. 17

    Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature.

    Sivasubramanian G, Chandrasekar PH

    Expert opinion on pharmacotherapy 2022; (23(5)):543-549 doi:10.1080/14656566.2022.2032645.

    PMID: 35099351
  18. 18

    Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.

    Beck KR, Telisman L, van Koppen CJ, et al.

    The Journal of steroid biochemistry and molecular biology 2020; (199()):105605 doi:10.1016/j.jsbmb.2020.105605.

    PMID: 31982514

This page is for informational purposes only and does not constitute medical advice. An infectious-disease or lung specialist should guide your antifungal treatment, drug-level monitoring, and response to side effects.